A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This was the first evaluation of the effects of LCZ696 on local and regional measures of aortic stiffness in subjects with mild to moderate hypertension and widened pulse pressure. The results of this exploratory study will help to understand the mechanism of action of LCZ696 and used to inform the design of future clinical studies with LCZ696 in subjects with cardiovascular diseases.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Amlodipine; LCZ 696; Olmesartan; Olmesartan Medoxomil; Sacubitril and valsartan sodium hydrate drug combination; Valsartan

Criteria

Key Inclusion Criteria:

• Subjects with essential hypertension, untreated or currently taking antihypertensive therapy

Key exclusion Criteria:

• women of child bearing potential (WOCBP) if not on highly effective contraception

• Malignant or severe hypertension (grade 3 of WHO classification)

• History or evidence of a secondary form of hypertension

• Transient ischemic cerebral attack (TIA) during the 12 months prior to screening or any history of stroke.

• Previous or current diagnosis of heart failure (New York Heart Association Class II-IV).